News: The Latest
Press Releases
Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine, BCA356, at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Contact Information
GENERAL
BUSINESS DEVELOPMENT
MEDIA
Chris Railey
chris@tenbridgecommunications.com
INVESTORS
Sarah McCabe
Sarah.McCabe@sternir.com
Presentations
Poster Presentation: A novel bispecific BCA356 targeting tumor antigen CAIX conjugated to an attenuated IL-12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 2022
Webinar: Clinical Update on BCA101: Overview and Discussion of Newly Presented Data
Presented by Bicara Therapeutics
September 2022
Poster Presentation: A Phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid cancers
American Society of Clinical Oncology
June 2022
Poster Presentation: Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGF-β Signaling, as a novel single-agent immunotherapy
Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 2021
Digital Presentation: First-in-human Phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers
American Society of Clinical Oncology
June 2021